BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 26315810)

  • 1. Crushed Versus Integral Tablets of Ticagrelor in ST-Segment Elevation Myocardial Infarction Patients: A Randomized Pharmacokinetic/Pharmacodynamic Study.
    Alexopoulos D; Barampoutis N; Gkizas V; Vogiatzi C; Tsigkas G; Koutsogiannis N; Davlouros P; Hahalis G; Nylander S; Parodi G; Xanthopoulou I
    Clin Pharmacokinet; 2016 Mar; 55(3):359-67. PubMed ID: 26315810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Franchi F; Rollini F; Rivas A; Wali M; Briceno M; Agarwal M; Shaikh Z; Nawaz A; Silva G; Been L; Smairat R; Kaufman M; Pineda AM; Suryadevara S; Soffer D; Zenni MM; Bass TA; Angiolillo DJ
    Circulation; 2019 Apr; 139(14):1661-1670. PubMed ID: 30630341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Escalating Loading Dose Regimens of Ticagrelor in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Results of a Prospective Randomized Pharmacokinetic and Pharmacodynamic Investigation.
    Franchi F; Rollini F; Cho JR; Bhatti M; DeGroat C; Ferrante E; Dunn EC; Nanavati A; Carraway E; Suryadevara S; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2015 Sep; 8(11):1457-1467. PubMed ID: 26404199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction.
    Alexopoulos D; Xanthopoulou I; Gkizas V; Kassimis G; Theodoropoulos KC; Makris G; Koutsogiannis N; Damelou A; Tsigkas G; Davlouros P; Hahalis G
    Circ Cardiovasc Interv; 2012 Dec; 5(6):797-804. PubMed ID: 23169985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Prehospital Crushed Prasugrel Tablets in Patients With ST-Segment-Elevation Myocardial Infarction Planned for Primary Percutaneous Coronary Intervention: The Randomized COMPARE CRUSH Trial.
    Vlachojannis GJ; Wilschut JM; Vogel RF; Lemmert ME; Delewi R; Diletti R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Angiolillo DJ; Krucoff MW; Van Mieghem NM; Smits PC
    Circulation; 2020 Dec; 142(24):2316-2328. PubMed ID: 33315489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of intravenous fentanyl compared with morphine on ticagrelor absorption and platelet inhibition in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: rationale and design of the PERSEUS randomized trial.
    Degrauwe S; Roffi M; Lauriers N; Muller O; Masci PG; Valgimigli M; Iglesias JF
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):158-163. PubMed ID: 30101278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study.
    Adamski P; Sikora J; Laskowska E; Buszko K; Ostrowska M; Umińska JM; Sikora A; Skibińska N; Sobczak P; Adamska U; Rość D; Kubica A; Paciorek P; Marszałł MP; Navarese EP; Gorog DA; Kubica J
    PLoS One; 2017; 12(10):e0186013. PubMed ID: 29023473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: The inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial.
    Venetsanos D; Sederholm Lawesson S; Swahn E; Alfredsson J
    Thromb Res; 2017 Jan; 149():88-94. PubMed ID: 27773347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial.
    Kubica J; Adamski P; Ostrowska M; Sikora J; Kubica JM; Sroka WD; Stankowska K; Buszko K; Navarese EP; Jilma B; Siller-Matula JM; Marszałł MP; Rość D; Koziński M
    Eur Heart J; 2016 Jan; 37(3):245-52. PubMed ID: 26491112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study.
    Niezgoda P; Sikora J; Barańska M; Sikora A; Buszko K; Siemińska E; Marszałł MP; Siller-Matula JM; Jilma B; Alexopoulos D; Fabiszak T; Kubica J
    Thromb Haemost; 2017 Apr; 117(4):718-726. PubMed ID: 28203684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial.
    Kubica J; Adamski P; Ostrowska M; Koziński M; Obońska K; Laskowska E; Obońska E; Grześk G; Winiarski P; Paciorek P
    Trials; 2015 Apr; 16():198. PubMed ID: 25925591
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study.
    Silvain J; Storey RF; Cayla G; Esteve JB; Dillinger JG; Rousseau H; Tsatsaris A; Baradat C; Salhi N; Hamm CW; Lapostolle F; Lassen JF; Collet JP; Ten Berg JM; Van't Hof AW; Montalescot G
    Thromb Haemost; 2016 Aug; 116(2):369-78. PubMed ID: 27196998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crushed Prasugrel Tablets in Patients With STEMI Undergoing Primary Percutaneous Coronary Intervention: The CRUSH Study.
    Rollini F; Franchi F; Hu J; Kureti M; Aggarwal N; Durairaj A; Park Y; Seawell M; Cox-Alomar P; Zenni MM; Guzman LA; Suryadevara S; Antoun P; Bass TA; Angiolillo DJ
    J Am Coll Cardiol; 2016 May; 67(17):1994-2004. PubMed ID: 27012781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
    Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
    J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of oral P2Y12 inhibitors during the acute phase of a myocardial infarction: A systematic review.
    Khan N; Cox AR; Cotton JM
    Thromb Res; 2016 Jul; 143():141-8. PubMed ID: 27259210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamic Effects of Pre-Hospital Administered Crushed Prasugrel in Patients With ST-Segment Elevation Myocardial Infarction.
    Vogel RF; Delewi R; Angiolillo DJ; Wilschut JM; Lemmert ME; Diletti R; van Vliet R; van der Waarden NWPL; Nuis RJ; Paradies V; Alexopoulos D; Zijlstra F; Montalescot G; Krucoff MW; van Mieghem NM; Smits PC; Vlachojannis GJ
    JACC Cardiovasc Interv; 2021 Jun; 14(12):1323-1333. PubMed ID: 34167672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ticagrelor pharmacokinetics and pharmacodynamics in patients with NSTEMI after a 180-mg loading dose.
    Holm M; Tornvall P; Westerberg J; Rihan Hye S; van der Linden J
    Platelets; 2017 Nov; 28(7):706-711. PubMed ID: 28150519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics of ticagrelor and AR-C124910XX in patients with prior myocardial infarction
.
    Röshammar D; Bergstrand M; Andersson T; Storey RF; Hamrén B
    Int J Clin Pharmacol Ther; 2017 May; 55(5):416-424. PubMed ID: 28139972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet effect of prasugrel and ticagrelor in patients with ST-segment elevation myocardial infarction.
    Kerneis M; Silvain J; Abtan J; Hauguel M; Barthélémy O; Payot L; Brugier D; Galier S; Collet JP; Montalescot G
    Arch Cardiovasc Dis; 2015 Oct; 108(10):502-10. PubMed ID: 26113480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study.
    Parodi G; Valenti R; Bellandi B; Migliorini A; Marcucci R; Comito V; Carrabba N; Santini A; Gensini GF; Abbate R; Antoniucci D
    J Am Coll Cardiol; 2013 Apr; 61(15):1601-6. PubMed ID: 23500251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.